AbbVie Presents Long-Term IBD Outcomes for SKYRIZI and RINVOQ at UEGW 2026

AbbVie announced the presentation of 20 new scientific abstracts at the 2026 United European Gastroenterology (UEG) Week, highlighting long-term clinical and endoscopic outcomes for its inflammatory bowel disease (IBD) therapies, SKYRIZI (risankizumab) and RINVOQ (upadacitinib). Data for risankizumab in ulcerative colitis showed sustained clinical and endoscopic remission up to three years, while as-observed analyses for upadacitinib in Crohn's disease demonstrated maintained clinical and endoscopic outcomes through approximately four years of treatment.